ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
TRT Health Care Cost Savings
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 194727" data-attributes="member: 3"><p><strong>TRT: Cost-effective Improvement, and Cost Savings</strong></p><p></p><p>Through its beneficial impact on clinical parameters and risk of comorbidity, testosterone therapy also appears to be a cost-effective and cost-saving intervention. Economic models in Sweden and the UK have demonstrated the benefits of testosterone therapy on health-care systems as a whole, through its effect of reducing comorbidity risk.40,43</p><p></p><p>In Sweden, lifetime treatment of male hypogonadism with testosterone undecanoate was shown to be cost-effective, with an incremental cost-effectiveness ratio (ICER) of €19,720 (in 2009 euros) per quality-adjusted life year, vs no treatment.43 This model incorporated the effects of testosterone undecanoate treatment on reducing risks of cardiovascular events, T2DM, fractures, depression, and death in hypothetical sample of 100,000 men with late-onset hypogonadism.43 A one-way sensitivity analysis that altered the risk of comorbidities, drug cost and age, confirmed the ICER results were robust, with changes to the risk of T2DM causing the most variation. The primary drivers of increased cost were the cost of testosterone undecanoate treatment itself, and the greater indirect cost associated with reduced mortality risk (and therefore longer survival) within the treated population; however, these increased costs were partially compensated by the reduced cost of treating comorbidities and complications.43</p><p></p><p>In the UK, treatment of male hypogonadism in males aged ≥40 with intramuscular testosterone undecanoate was also shown to have a positive cost impact, vs no treatment over a 10-year time horizon.40 This analysis included resource use and unit costs only for patients treated with IM testosterone undecanoate and calculated average direct annual costs of managing each comorbidity from the NHS national tariff in both scenarios. Across all comorbidities, a total of 408,481 patients were estimated to receive treatment with testosterone undecanoate and 913,676 patients did not receive testosterone therapy over 10 years. Overall, additional costs of drug, administration, and monitoring were outweighed by reductions in the inpatient cost of managing major comorbidities (T2DM, obesity, CVD, and osteoporosis).40 Specifically, individual yearly testosterone therapy costs of £687 were outweighed by a £3732 reduction in the yearly inpatient cost of treating comorbidities, of which approximately half was accounted for by cardiovascular disease-related cost savings (£1727) [Figure 2].40 However, this was considered to be an underestimation given possible interaction between comorbidities were not examined and the costs of drugs used to manage comorbidities were not included in this analysis.</p><p></p><p>[ATTACH=full]12601[/ATTACH]</p><p></p><p></p><p>Source:</p><p><a href="https://www.dovepress.com/burden-of-male-hypogonadism-and-major-comorbidities-and-the-clinical-e-peer-reviewed-fulltext-article-CEOR" target="_blank">Burden of Male Hypogonadism and Major Comorbidities, and the Clinical, Economic, and Humanistic Benefits of Testosterone Therapy: A Narrative Review</a></p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 194727, member: 3"] [B]TRT: Cost-effective Improvement, and Cost Savings[/B] Through its beneficial impact on clinical parameters and risk of comorbidity, testosterone therapy also appears to be a cost-effective and cost-saving intervention. Economic models in Sweden and the UK have demonstrated the benefits of testosterone therapy on health-care systems as a whole, through its effect of reducing comorbidity risk.40,43 In Sweden, lifetime treatment of male hypogonadism with testosterone undecanoate was shown to be cost-effective, with an incremental cost-effectiveness ratio (ICER) of €19,720 (in 2009 euros) per quality-adjusted life year, vs no treatment.43 This model incorporated the effects of testosterone undecanoate treatment on reducing risks of cardiovascular events, T2DM, fractures, depression, and death in hypothetical sample of 100,000 men with late-onset hypogonadism.43 A one-way sensitivity analysis that altered the risk of comorbidities, drug cost and age, confirmed the ICER results were robust, with changes to the risk of T2DM causing the most variation. The primary drivers of increased cost were the cost of testosterone undecanoate treatment itself, and the greater indirect cost associated with reduced mortality risk (and therefore longer survival) within the treated population; however, these increased costs were partially compensated by the reduced cost of treating comorbidities and complications.43 In the UK, treatment of male hypogonadism in males aged ≥40 with intramuscular testosterone undecanoate was also shown to have a positive cost impact, vs no treatment over a 10-year time horizon.40 This analysis included resource use and unit costs only for patients treated with IM testosterone undecanoate and calculated average direct annual costs of managing each comorbidity from the NHS national tariff in both scenarios. Across all comorbidities, a total of 408,481 patients were estimated to receive treatment with testosterone undecanoate and 913,676 patients did not receive testosterone therapy over 10 years. Overall, additional costs of drug, administration, and monitoring were outweighed by reductions in the inpatient cost of managing major comorbidities (T2DM, obesity, CVD, and osteoporosis).40 Specifically, individual yearly testosterone therapy costs of £687 were outweighed by a £3732 reduction in the yearly inpatient cost of treating comorbidities, of which approximately half was accounted for by cardiovascular disease-related cost savings (£1727) [Figure 2].40 However, this was considered to be an underestimation given possible interaction between comorbidities were not examined and the costs of drugs used to manage comorbidities were not included in this analysis. [ATTACH type="full"]12601[/ATTACH] Source: [URL='https://www.dovepress.com/burden-of-male-hypogonadism-and-major-comorbidities-and-the-clinical-e-peer-reviewed-fulltext-article-CEOR']Burden of Male Hypogonadism and Major Comorbidities, and the Clinical, Economic, and Humanistic Benefits of Testosterone Therapy: A Narrative Review[/URL] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
X (Twitter)
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
TRT Health Care Cost Savings
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top